GRM1 and COVID-19: These results suggest that LHQW may be effective in treating psychological disorder symptoms in mild-to-moderate COVID-19 by targeting neurological disease-related targets (GRM1 and GRM5) through arctiin, corymbosin, and aloe-emodin.